Replies to post #328525 on Amarin Corp Plc (AMRN)

[momoney24]

Surprised this isn’t attracting more attention here. If I understand this correctly, this is pretty big news...

[ralphey]

LOvaza can have the trigs >500 market - works better in that setting anyway ...

[HDGabor]

m-

united healthcare will no longer be covering Vascepa or generic Icosapent Ethyl for severe hypertriglyceridemia (Triglycerides >500). Instead they will cover generic Lovaza and/or Fibrates

To cancel the VHTG indication from the label is futile, the indication will exist independently from Vascepa ('s label) ... however modify the coverage agreements - terminate the VHTG part - is a brilliant step. Let's hope all HCP will do the same. (Assumping it is Amarin's action, plan going forward ... let the 10% of the market for the gV WITHOUT coverage.)

Best,
G

[Number sleven]

Massulo, Do you or anyone else think it would be a viable strategy to go after every insurance company that is willing to reimburse the cost of gv for the CVD indication? Also do you think this move by United Healthcare is in direct response to the inclusion of Health Net in the infringment suit?
Sleven,

[dukesking]

Wow! This is great news if it’s true. Has this been confirmed?

[HinduKush]

Makes total strategic and medical sense:

United healthcare update:
Starting May 1 2021, united healthcare will no longer be covering Vascepa or generic Icosapent Ethyl for severe hypertriglyceridemia (Triglycerides >500). Instead, they will cover generic Lovaza and/or Fibrates
The Reduce-It indication for cardiovascular risk reduction on top of statin will remain after prior authorization is complete

IF the HyperTG indication is just short term to reduce the risk for pancreatitis, then the use of Lovaza or fibrates or anything else is fine. IF the reason for chronic long term use is CV event reduction, then the only choice should be Vascepa.
HK